CTLA4 and pancreatic ductal adenocarcinoma: Anti-PD-L1 and anti-CTLA-4 blockade likely have different immunologic effects and others have found that baseline TCR clonality can produce differential outcomes with each therapy in the context of pancreatic ductal adenocarcinoma [15], so the finding that increasing TCF is associated with worse survival after anti-PD-L1 blockade but improved survival after anti-CTLA-4 blockade may not be contradictory.